GWM
SRPT icon

Gilpin Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Gilpin Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$164 Hold
9
– – ﹤0.01% 1191
2026
Q2 		$162 Buy
9
+1
+13% +$19 ﹤0.01% 960
2026
Q1 		$175 Hold
8
– – ﹤0.01% 877
2025
Q4 		$173 Buy
+8
New +$169 ﹤0.01% 701

Other funds holding SRPT

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
MAFA
MJT & Associates Financial Advisory Monteviceo, Minnesota $155M AUM 15.7% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Gilpin Wealth Management's SRPT Position: Q3 2026 in Review

Gilpin Wealth Management held its Sarepta Therapeutics (SRPT) position steady in Q3 2026 at 9 shares worth $164. The position accounts for ﹤0.01% of the portfolio, ranked #1191.

Gilpin Wealth Management first reported a position in SRPT in Q4 2025 and has held it in 4 quarters since. The position peaked at $175 in Q1 2026. 9 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

  • Gilpin Wealth Management held 9 shares of Sarepta Therapeutics worth $164 as of Q3 2026.
  • Gilpin Wealth Management left its Sarepta Therapeutics share count unchanged in Q3 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #1191 holding.
  • Gilpin Wealth Management first reported a position in Sarepta Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Gilpin Wealth Management's Sarepta Therapeutics position peaked at $175 in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.